NICE recommends inhaled mucolytic in cystic fibrosis

New guidance from NICE approves the use of the dry powder mannitol inhaler, Bronchitol, in patients with rapidly deteriorating disease who are unable to take rhDNase or other osmotic agents.

The build-up of mucus in the lungs (as pictured in this X-ray) is broken down by the influx of water into the airway following inhalation of hyperosmotic mannitol | SCIENCE PHOTO LIBRARY
The build-up of mucus in the lungs (as pictured in this X-ray) is broken down by the influx of water into the airway following inhalation of hyperosmotic mannitol | SCIENCE PHOTO LIBRARY

Adult patients with cystic fibrosis are set to benefit from the approval of the Pharmaxis product Bronchitol following the publication of the latest technology appraisals from NICE. However, use is restricted to patients:

  • who cannot receive recombinant human deoxyribonuclease (rhDNase) owing to ineligibility, intolerance or who have not adequately responded to rhDNase and
  • whose forced expiratory volume in 1 second (FEV1) has declined by >2% annually and
  • for whom other osmotic agents are inappropriate.

Initiation and dosage recommendations

Before starting dosing with the inhaler, patients must be assessed for bronchial hyperresponsiveness to inhaled mannitol according to the SPC. Following initial dose assessment, the recommended dosage is 400mg (contents of 10 capsules) inhaled using the provided inhaler twice daily.

NICE guidance on mannitol dry powder inhalation for cystic fibrosis

Follow MIMS on Twitter


MIMS Clinics

Prescribing news and resources for key therapeutic areas, collated by the MIMS editors.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS bulletins

News and updates straight to your inbox.

Prescribing Update: Fortnightly news bulletin
Alert:
Urgent prescribing updates
Spotlight: Disease-themed monthly round-up

Sign me up

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases

Promo Image

Clinical calculators

Handy calculators and conversions for primary care.